Biosimilars Or Biobetters: Make Your Decisions Wisely
Downloads
There is an increasing interest in biosimilars and biobetters, with the total number of reported development candidates equaling the number of innovative development compounds. Even assuming attrition in development, the biosimilars market will suffer from significant competition in the future. The present article builds on a financial modeling approach that takes into account development cost and risk and minimum required sales to yield a robustly positive financial value. In reference to the commercial success of the originator, such models can facilitate portfolio decisions. Predictive success criteria for biosimilars on the one hand and biobetters on the other hand are presented.
Barbosa M. 2011. Immunogenicity of
biotherapeutics in the context of developing
biosimilars and biobetters. Drug Discovery Today
: 345-353.
Belsey MJ, Harris LM, Das RR, Chertkow J. 2006.
Biosimilars: initial excitement gives way to reality.
Nature Reviews Drug Discovery 5: 535-536.
Bode-Greuel KM, Greuel JM. 2005. Determining
the value of drug development candidates and
technology platforms. Journal of Commercial
Biotechnology 11: 155-170.
Bode-Greuel KM, Nickisch K. 2014. Deciding
between biobetter versus biosimilar development
options based on net present value calculations.
Journal of Commercial Biotechnology 20: 21-31.
Chapman AP. 2002. PEGylated antibodies and
antibody fragments for improved therapy: a
therapy. Advanced Drug Delivery Reviews 54: 531-
De Groot AS, Scott DS. 2007. Immunogenicity of
protein therapeutics. Trends in Immunology 28:
- 490.
Herwadkar A, Banga AK. 2012. Peptide and
protein transdermal drug delivery. Drug Discovery
Today 9: 147-154.
Kalyanaram G, Robinson WT, Urban GL. 1995.
Order of market entry: established empirical
generalizations, emerging empirical
generalizations, and future research. Marketing
Science 14: 212-221.
King S. 2012. FirstWord Pharma, December 8th
Malkin BJ, Wasson AS. 2011. Food and Drug Law
Institute update, 60-64
Nickisch K, Bode-Greuel KM. 2013. NPV
modelling for the selection of value-creating
biosimilar development candidates. Journal of
Commercial Biotechnology 19: 24-32. Platis D, Labrou NE. 2008. Chemical and genetic
engineering strategies to improve the potency of
pharmaceutical proteins and enzymes. Current
Medicinal Chemistry 15: 1940-55. Rader R. 2013. Bioprocess International 11: 17-23.
Urban GL, Carter T, Gaskin S, Mucha Z. 1986.
Market share rewards to pioneering brands: an
empirical analysis and strategic implications.
Management Science 32: 645-659.
Wildiers H et al. 2013. T-DM1 for HER2-positive
metastatic breast cancer (MBC): Primary results
from TH3RESA, a phase 3 study of T-DM1 vs
treatment of physician's choice. European Cancer
Congress, abstract #LBA15.
All Content should be original and unpublished.
